Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer ; volume:5 ; number:1 ; day:8 ; month:8 ; year:2016 ; pages:1-6 ; date:12.2015
Experimental hematology & oncology ; 5, Heft 1 (8.8.2016), 1-6, 12.2015
- Creator
-
Berz, David
- Contributor
-
Raymond, Victoria M.
Garst, Jordan H.
Erlander, Mark G.
SpringerLink (Online service)
- DOI
-
10.1186/s40164-016-0052-3
- URN
-
urn:nbn:de:1111-201609058416
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Berz, David
- Raymond, Victoria M.
- Garst, Jordan H.
- Erlander, Mark G.
- SpringerLink (Online service)
Other Objects (12)
Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer
Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer
Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation